In the competitive field of Peptide Synthesis, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Peptide Synthesis technology and learn how to protect your intellectual property.

Get complete Patent Opposition Report for Peptide Synthesis

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Peptide Synthesis industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Peptide Synthesis industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Peptide Synthesis industry

EP3202785Method For The Production Of A Glycosylated ImmunoglobulinCHUGAI SEIYAKU KABUSHIKI KAISHAFeb 10, 2025STRAWMAN
EP3237004Predicting Outcome Of Treatment With An Anti- 4 7 Integrin AntibodyTAKEDA PHARMACEUTICALFeb 7, 2025POLPHARMA BIOLOGICS
EP3270966Combination Of Hdac Inhibitor And Anti-Pd-1 Antibody For Treatment Of CancerSYNDAX PHARMACEUTICALSJan 31, 2025MAIWALD
EP3515475Chimeric Antigen Receptor (Car) That Targets Chemokine Receptor Ccr4 And Its UseTHE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSJan 30, 2025WEICKMANN & WEICKMANN PARTMBB
EP3411476Enhanced Production Of ImmunoglobulinsTRIANNIJan 24, 2025REGENERON PHARMACEUTICALS
EP3889181Methods For Treating Atopic Dermatitis By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJan 24, 2025DEHMEL & BETTENHAUSEN PATENTANWALTE PARTMBB
EP3889181Methods For Treating Atopic Dermatitis By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYJan 23, 2025SECERNA
EP4069368Enhancing Blood-Brain Barrier Drug Transport By Targeting Endogenous RegulatorsTHE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSJan 15, 2025DORRIES
EP3191120Use Of Il-17 Antagonists To Inhibit The Progression Of Structural Damage In Psoriatic Arthritis PatientsNOVARTISJan 10, 2025HAMPTON KNOWLES
EP3307765Recombinant Protein Fiber Yarns With Improved PropertiesBOLT THREADSJan 9, 2025ZWICKER SCHNAPPAUF & PARTNER PATENTANWALTE PARTG MBB

To stay ahead in the competitive Peptide Synthesis industry, companies are constantly innovating. Here are the top patents facing oppositions in the Peptide Synthesis industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2188302Nov 1, 2017Prevention Of Disulfide Bond Reduction During Recombinant Production Of PolypeptidesGENENTECH11
EP2462158Jan 10, 2018Method To Improve Virus Removal In Protein PurificationF HOFFMANN LA ROCHE11
EP2825558May 15, 2019Combination Therapy For The Treatment Of Ovarian CancerFHOFFMANN LA ROCHE10
EP2971040Sep 19, 2018Methods Of Cell CultureMOMENTA PHARMACEUTICALS10
EP3177645Feb 17, 2021Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLUDWIG MAXIMILIANS UNIVERSITT MNCHEN10
EP2791160Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNATX10
EP3616720Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI10
EP2586788Nov 29, 2017Prevention Of Disulfide Bond Reduction During Recombinant Production Of PolypeptidesGENENTECH9
EP2766040May 15, 2019Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHE9
EP3322731Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB9